Search

Displaying results 2201 - 2210 of 10000 in total
  1. Drug

    Bismuth subsalicylate

    go.drugbank.com/drugs/DB01294
    ApprovedVet approved

    [A230728] It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that is used to temporarily treat discomforts of the stomach and gastrointestinal tract. … [A230733] Bismuth subsalicylate has been around for over 100 years: it was originally developed in 1901 for hygienic use and sanitation for cholera infection.

    Products: Kao-tin Peppermint Flavor
  2. Drug

    Dimethyl fumarate

    go.drugbank.com/drugs/DB08908
    ApprovedInvestigational

    in response to oxidative stress. … [A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood.

  3. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    Delgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024. … [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]

  4. Drug

    Polysorbate 20

    go.drugbank.com/drugs/DB11178
    Approved

    It is also an excipient that stabilizes emulsions and suspensions in pharmaceutical products and lubricant in ophthalmic solutions. … Polysorbate 20 is a wetting agent in food products, as well as washing agent, stabilizer and solubilizer in labratory assays and industrial applications.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

  6. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer. … [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific

  7. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.

  8. Drug

    Phendimetrazine

    go.drugbank.com/drugs/DB01579
    ApprovedIllicit

    Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.

  9. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December

  10. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylose has also been used as a diagnostic agent to observe malabsorption. … The dextrorotary form of xylose, D-xylose, refers usually to the endogenously occurring form of the sugar in living things. The levorotary form, L-xylose, can refer to the form that is synthesized.